Servicio Madrileño de Salud
The organisation Servicio Madrileño de Salud (SERMAS) is the administrative and management structure that integrates every public hospital and every public health service in the Madrid Regional Health System. SERMAS, in the FP7 and HORIZON 2020, is the legal representative (beneficiary) of every public hospital of the Madrid Regional Health System. Usually SERMAS delegates authority to the Hospital’s General Director to manage the research project favourably evaluated by the Commission. In this project, SERMAS (beneficiary) is the legal representative of Hospital Clínico San Carlos and delegates authority to the Hospital’s General Director to manage research projects. Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (FIB HCSC) is a third party of Hospital Clínico San Carlos: Third party making their resources available to a beneficiary free of charge (Art.12). Collaboration between SERMAS and FIB HCSC is carried out through a prior collaboration agreement, by means of which the latter handles the financial and administrative aspects of the Hospital’s involvement in research projects, including all issues relating to the employment and payment of additional personnel, purchase of equipment and consumables, etc. The Foundation is in the premises of the Hospital. In accordance to it, the EC contribution is directly paid to this Foundation as Third Party, and not to the beneficiary. Hospital Clínico San Carlos is a reference centre at national and international level for its facilities and its professionals. The Hospital has over 5,000 employees and 1000 beds, and is the main referral centre in the training of health professionals at the Complutense University of Madrid. HCSC has the experience & capabilities required to develop and manage internationals projects as shown by its current participation in 11 international projects: 3 projects are financed through the 7th Framework Program, 5 projects are financed through HORIZON 2020, 2 projects are financed through the Innovative Medicines Initiative (IMI JTI), and 1 project is financed by the National Institutes of Health (NIH).